UNION therapeutics announces expansion to India of the PROTECT-V Phase 2/3 study of niclosamide nasal spray as COVID-19 prophylaxis
· The PROTECT-V Phase 2/3 platform study investigating niclosamide nasal spray as prophylactic treatment for COVID-19 in kidney patients will now be conducted in both the UK and India · UK investigators have enrolled over 1000 patients in the study across the UK, and with the expansion of the study to India, the study will be further strengthened, and the conclusion potentially accelerated · A significant unmet medical need persists to protect kidney patients, as well as other immunocompromised patients, as they may not respond sufficiently to COVID-19 vaccination Hellerup, Denmark,